These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26392503)

  • 1. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
    Jensen SB; Serre SB; Humes DG; Ramirez S; Li YP; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7426-36. PubMed ID: 26392503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
    Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
    Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
    Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Imhof I; Simmonds P
    Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
    Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V; Mirabelli C; Salpini R; Dimonte S; Artese A; Costa G; Mercurio F; Svicher V; Parrotta L; Bertoli A; Ciotti M; Di Paolo D; Sarrecchia C; Andreoni M; Alcaro S; Angelico M; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2012; 7(7):e39652. PubMed ID: 22792183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
    Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.
    Murai K; Shimakami T; Welsch C; Shirasaki T; Liu F; Kitabayashi J; Tanaka S; Funaki M; Omura H; Nishikawa T; Sumiyadorj A; Honda M; Kaneko S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.